Pharmaceutical approval update.

Fluticasone furoate/vilanterol inhalation powder (Breo Ellipta) for chronic obstructive pulmonary disease; atorvastatin/ezetimibe tablets (Liptruzet) for reducing low-density lipoproteincholesterol; and radium 223 dichloride (Xofigo) injection for late-stage, castrationresistant prostate cancer.